Repligen Corporation launched the CTech™ SoloVPE® PLUS System, enhancing UV-Vis measurement accuracy and speed for biopharmaceutical manufacturing.
Quiver AI Summary
Repligen Corporation announced the launch of its CTech™ SoloVPE® PLUS System, an advanced UV-based Variable Pathlength Technology designed for biopharmaceutical manufacturers. This system enhances at-line ultraviolet-visible concentration measurements within biological production workflows, offering speed and accuracy without the need for sample dilution. As the industry transitions to higher drug concentrations, the SoloVPE PLUS System addresses the demand for faster and more reliable analytical tools, delivering precise measurements in under 30 seconds. Key benefits include streamlined workflows, increased data collection speed, improved sensitivity, and direct sample measurement. This launch is part of Repligen's ongoing commitment to innovation in bioprocessing technologies, with further product developments anticipated in 2025.
Potential Positives
- Repligen Corporation has launched the CTech™ SoloVPE® PLUS System, which is described as the most advanced UV-based Variable Pathlength Technology system available, enhancing its product offerings in bioprocessing technology.
- The SoloVPE PLUS System significantly streamlines workflows, reducing process steps by 70%, which can lead to improved efficiency and cost savings for biopharmaceutical manufacturers.
- This new system doubles the speed of data collection, allowing for results in less time, supporting faster decision-making and greater operational efficiency in complex production environments.
- The innovative features of the SoloVPE PLUS System enhance sensitivity and reproducibility, providing precise measurement across a wide range of concentrations without requiring dilution, potentially benefiting a variety of biopharmaceutical applications.
Potential Negatives
- The press release contains forward-looking statements that caution investors about uncertainties and risks, indicating that actual results may differ from the anticipated outcomes related to the SoloVPE PLUS System.
- There is no specific financial performance data or projections provided regarding the expected impact of the SoloVPE PLUS System, which may raise concerns about the company's future revenue growth.
- The release does not address potential competition in the market for similar bioprocessing technologies, leaving a gap in understanding the competitive landscape for the SoloVPE PLUS System.
FAQ
What is the CTech™ SoloVPE® PLUS System?
The CTech™ SoloVPE® PLUS System is an advanced UV-based Variable Pathlength Technology system designed for accurate concentration measurement in biopharmaceutical manufacturing.
How does the SoloVPE PLUS System improve bioprocessing?
The SoloVPE PLUS System enhances speed, accuracy, and ease-of-use, streamlining workflows and meeting the industry's demand for efficient analytical tools.
What makes SoloVPE PLUS faster than previous models?
The SoloVPE PLUS System doubles the speed of data collection, providing concentration results in under 30 seconds without sample dilution.
What applications can the SoloVPE PLUS System support?
It supports applications such as protein concentration measurement, nucleic acids quantitation, and mRNA measurement in therapeutics.
How does Repligen ensure data management with SoloVPE PLUS?
The system utilizes CTech™ ViPER® ANLYTX Software for optimized data management, integrating SQL for storage and standardized communication through OPC-UA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RGEN Insider Trading Activity
$RGEN insiders have traded $RGEN stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:
- ANTHONY HUNT has traded it 5 times. They made 0 purchases and 5 sales, selling 46,437 shares.
- RALF KURIYEL (Senior VP, R&D) has traded it 3 times. They made 0 purchases and 3 sales, selling 11,613 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RGEN Hedge Fund Activity
We have seen 225 institutional investors add shares of $RGEN stock to their portfolio, and 235 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,783,806 shares (+38.7%) to their portfolio in Q3 2024
- CHAMPLAIN INVESTMENT PARTNERS, LLC added 850,345 shares (+149.0%) to their portfolio in Q3 2024
- WELLINGTON MANAGEMENT GROUP LLP removed 784,065 shares (-100.0%) from their portfolio in Q3 2024
- FMR LLC removed 641,519 shares (-44.4%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 636,708 shares (-84.2%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 512,438 shares (+14970.4%) to their portfolio in Q3 2024
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 482,906 shares (-94.6%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE
®
PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in complex biological production workflows, from process development scale through cGMP manufacturing.
As the bioprocess industry shifts toward higher drug concentration formulations to improve efficiency and reduce production costs, there has been a growing need for faster, more reliable and more accurate analytical tools. The SoloVPE PLUS System addresses this need, utilizing variable pathlength spectroscopy to deliver precise concentration measurements in under 30 seconds, without the need for dilution or background correction.
This innovative technology is a significant addition to Repligen’s process analytics portfolio, advancing the company’s at-line capabilities and complementing both its in-line, real-time FlowVPX
®
System and fully integrated RPM™ (Real-time Process Management) TFF Systems. Applications for the SoloVPE PLUS System include measurement of protein concentration (such as for antibody-based drugs, including ADC drug-to-antibody ratio), quantitation of nucleic acids (DNA/RNA) and measurement of mRNA in mRNA-based therapeutics.
Olivier Loeillot, President and Chief Executive Officer at Repligen said, “The next-generation SoloVPE PLUS System is a success for our development team, delivering on the goal to achieve a new level of speed, precision and reproducibility. It’s an exciting advance for Repligen - and just the first of many new product launches we have planned for 2025.”
Kola Otitoju, Senior Vice President and Global Head of Process Analytics, said, “Repligen is at the forefront of PAT innovation, and the new SoloVPE PLUS System showcases our ability to evolve our bioprocessing technologies to meet our customers’ needs. The SoloVPE PLUS System delivers on the key performance factors required to support faster decision-making and greater efficiency, helping our customers improve both their productivity and bottom line."
The SoloVPE PLUS System offers several key advantages over current UV-Vis spectroscopy offerings in the market:
Streamlined Workflow.
Reduces process steps by 70%, from a seven-step process to just two - measure and report.
Accelerated Acquisition Speed.
Doubles the speed of data collection, delivering results in half the time compared to the legacy SoloVPE System.
Enhanced Sensitivity and Reproducibility.
Measures the widest range of concentrations without dilution—mAbs from 0.01 mg/mL to 320 mg/mL, with an R²≥ 0.999.
Minimized Error-Prone Steps.
Direct measurement of samples eliminates the need for dilution or additional sample preparation.
Optimized Data Management.
The CTech™ ViPER
®
ANLYTX Software integrates SQL for data storage and retrieval, and OPC-UA for standardized communication, enabling a streamlined, agile, and connected system that supports real-time access and scalable bioprocessing operations.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at
www.repligen.com
, and follow us on
LinkedIn
.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, express or implied statements
or guidance regarding the impact of SoloVPE PLUS systems on Repligen’s future financial performance, customer adoption of the SoloVPE PLUS, the expected expansion of Repligen’s product lines, and other statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, as detailed in Repligen’s most recent Annual Report on Form 10-K, subsequently filed Quarterly Reports on Form 10-Q and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management’s current views and are based only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information or otherwise, that occur after the date hereof except as required by law.
Repligen Contact:
Sondra S. Newman
VP, Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ef007654-8d91-436b-80aa-1223559a5a0f
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
